Curis Inc., of Lexington, Mass., reported a net loss of $12.3 million for the year ended Dec. 31, 2013, as compared to a net loss of $16.4 million in 2012. Revenues were $15 million as compared to $17 million in 2012. Revenues in 2012 and 2013 were generated from the company’s collaboration with Genentech. The decrease in revenues was primarily due to a decrease of $4 million in license revenues offset by an increase in royalty revenues earned from Genentech/Roche’s net sales of Erivedge, (vismodegib), a Hedgehog inhibitor, which gained FDA approval for advanced basal cell carcinoma, during 2013, and increased to $3.9 million in 2013, as compared to $1.5 million in 2012. As of Dec. 31, the company had cash totaling $68.9 million.